Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Operating Expenses for 4 consecutive years, with $56.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 648.12% to $56.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.7 million, a 648.12% increase, with the full-year FY2025 number at $56.7 million, up 648.12% from a year prior.
  • Other Operating Expenses was $56.7 million for Q4 2025 at Cartesian Therapeutics, up from $7.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $56.7 million in Q4 2025 to a low of $710000.0 in Q4 2023.
  • A 3-year average of $21.7 million and a median of $7.6 million in 2024 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: soared 967.46% in 2024, then surged 648.12% in 2025.
  • Cartesian Therapeutics' Other Operating Expenses stood at $710000.0 in 2023, then skyrocketed by 967.46% to $7.6 million in 2024, then soared by 648.12% to $56.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Other Operating Expenses are $56.7 million (Q4 2025), $7.6 million (Q4 2024), and $710000.0 (Q4 2023).